In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $24.11 down -2.74% from its previous closing price of $24.79. In other words, the price has decreased by -$2.74 from its previous closing price. On the day, 1.91 million shares were traded. BBIO stock price reached its highest trading level at $25.79 during the session, while it also had its lowest trading level at $24.0.
Ratios:
For a deeper understanding of BridgeBio Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.19 and its Current Ratio is at 3.19.
On September 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $46.Piper Sandler initiated its Overweight rating on September 04, 2024, with a $46 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 13 ’24 when KKR Genetic Disorder L.P. sold 5,800,000 shares for $25.75 per share. The transaction valued at 149,350,000 led to the insider holds 25,260,971 shares of the business.
KKR Genetic Disorder L.P. bought 5,800,000 shares of BBIO for $156,310,000 on Sep 13 ’24. On Aug 19 ’24, another insider, Kumar Neil, who serves as the Chief Executive Officer of the company, sold 27,389 shares for $24.69 each. As a result, the insider received 676,256 and left with 4,897,443 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 4556549120 and an Enterprise Value of 6031499264. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.92. Its current Enterprise Value per Revenue stands at 27.697 whereas that against EBITDA is -11.829.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $44.32, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -5.97%, while the 200-Day Moving Average is calculated to be -12.57%.
Shares Statistics:
For the past three months, BBIO has traded an average of 1.98M shares per day and 1696040 over the past ten days. A total of 175.08M shares are outstanding, with a floating share count of 146.91M. Insiders hold about 21.87% of the company’s shares, while institutions hold 77.86% stake in the company. Shares short for BBIO as of 1730332800 were 17199451 with a Short Ratio of 8.70, compared to 1727654400 on 18628832. Therefore, it implies a Short% of Shares Outstanding of 17199451 and a Short% of Float of 14.08.
